Early Tirofiban Administration After Intravenous Thrombolysis in Acute Ischemic Stroke

Prior treatment

• Received or plan to undergo bridge therapy;
• Being enrolled or having been enrolled in other clinical trial within 3 months prior to this clinical trial.;

Other illness

• Atrial fibrillation or suspected cardiac embolism;
• Accompanied by epileptic seizures;
• Active bleeding or tendency to bleed after receipt of intravenous thrombolysis;
• Digestive system bleeding, urinary system bleeding, hemorrhagic retinopathy or other systemic bleeding events within 1 year;
• Known allergy to tirofiban;

Lab values

• Severe renal or liver insufficiency; ALT or AST\>3 times of the upper limit of normal value or above; creatinine clearance rate\<30 mL/min, creatinine\>200μmol/L；

Other

• Large area of infarct indicated by radiological imaging(≥1/3 of middle cerebral artery supply area);
• Using antiplatelet, anticoagulant or fibrinolytic agents within 24h before recruitment;
• Life expectancy less than 3 months;
• Pregnant or lactating women;
• Patients who are unwilling to be followed up or likely to have poor treatment compliance;
• Other situations that the researcher deems unsuitable for inclusion in the study.

• Age≥18 years old;
• Clinically diagnosed as acute ischemic stroke and received standard dose (0.25mg/kg) of tenecteplase IVT within 4.5 hours of onset;
• Total National Institute of Health stroke scale (NIHSS)≥4 or single limb motor item score≥2, and total NIHSS≤15 after IVT;
• Tirofiban or placebo treatment can be initiated within 6h after IVT;
• mRS score before onset≤ 1;
• Intracranial hemorrhage is ruled out by CT head after IVT;